Phase I/II Study Evaluating AUTO4 in Patients With T Cell Receptor Beta Constant (TRBC)1 Positive T Cell Lymphoma
Autolus Limited
Autolus Limited
University of Chicago
Penn State University
Eastern Cooperative Oncology Group
National Institutes of Health Clinical Center (CC)
BeOne Medicines
City of Hope Medical Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Dana-Farber Cancer Institute
Acerta Pharma BV
Incyte Corporation
AstraZeneca
Ohio State University Comprehensive Cancer Center
National Cancer Institute (NCI)
Incyte Corporation
Hope Biosciences Research Foundation
Aileron Therapeutics, Inc.
Acerta Pharma BV
Fred Hutchinson Cancer Center
Masonic Cancer Center, University of Minnesota
Acerta Pharma BV
St. Jude Children's Research Hospital
University of Washington
Takeda
University of California, San Diego
CRISPR Therapeutics
Bristol-Myers Squibb
Incyte Corporation
National Cancer Institute (NCI)
Acerta Pharma BV
National Institutes of Health Clinical Center (CC)
Genmab
Sanofi
St. Jude Children's Research Hospital
University of California, San Diego
BeiGene
Seattle Children's Hospital
Stanford University
Incyte Corporation
M.D. Anderson Cancer Center
Emory University
University of Washington
National Institutes of Health Clinical Center (CC)
Hackensack Meridian Health
Georgetown University
Autolus Limited
City of Hope Medical Center
M.D. Anderson Cancer Center
Therapeutic Advances in Childhood Leukemia Consortium
Eisai Inc.